TY - JOUR AU - Cao, Y. AU - Arbiser, J. AU - D’Amato, R. J. AU - D’Amore, P. A. AU - Ingber, D. E. AU - Kerbel, R. PY - 2011 DA - 2011// TI - Forty-year journey of angiogenesis translational research JO - Sci Transl Med VL - 3 UR - https://doi.org/10.1126/scitranslmed.3003149 DO - 10.1126/scitranslmed.3003149 ID - Cao2011 ER - TY - JOUR AU - Folkman, J. PY - 1971 DA - 1971// TI - Tumor angiogenesis: therapeutic implications JO - N Engl J Med VL - 285 UR - https://doi.org/10.1056/NEJM197111182852108 DO - 10.1056/NEJM197111182852108 ID - Folkman1971 ER - TY - JOUR AU - Folkman, J. PY - 2007 DA - 2007// TI - Angiogenesis: an organizing principle for drug discovery? JO - Nat Rev Drug Discov VL - 6 UR - https://doi.org/10.1038/nrd2115 DO - 10.1038/nrd2115 ID - Folkman2007 ER - TY - JOUR AU - Cao, Y. AU - Langer, R. PY - 2010 DA - 2010// TI - Optimizing the delivery of cancer drugs that block angiogenesis JO - Sci Transl Med VL - 2 UR - https://doi.org/10.1126/scitranslmed.3000399 DO - 10.1126/scitranslmed.3000399 ID - Cao2010 ER - TY - JOUR AU - O’Reilly, M. S. AU - Boehm, T. AU - Shing, Y. AU - Fukai, N. AU - Vasios, G. AU - Lane, W. S. PY - 1997 DA - 1997// TI - Endostatin: an endogenous inhibitor of angiogenesis and tumor growth JO - Cell VL - 88 UR - https://doi.org/10.1016/S0092-8674(00)81848-6 DO - 10.1016/S0092-8674(00)81848-6 ID - O’Reilly1997 ER - TY - JOUR AU - O’Reilly, M. S. AU - Holmgren, L. AU - Shing, Y. AU - Chen, C. AU - Rosenthal, R. A. AU - Moses, M. PY - 1994 DA - 1994// TI - Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma JO - Cell VL - 79 UR - https://doi.org/10.1016/0092-8674(94)90200-3 DO - 10.1016/0092-8674(94)90200-3 ID - O’Reilly1994 ER - TY - JOUR AU - Cao, Y. AU - Xue, L. PY - 2004 DA - 2004// TI - Angiostatin JO - Semin Thromb Hemost VL - 30 UR - https://doi.org/10.1055/s-2004-822973 DO - 10.1055/s-2004-822973 ID - Cao2004 ER - TY - JOUR AU - Cao, Y. PY - 2001 DA - 2001// TI - Endogenous angiogenesis inhibitors and their therapeutic implications JO - Int J Biochem Cell Biol VL - 33 UR - https://doi.org/10.1016/S1357-2725(01)00023-1 DO - 10.1016/S1357-2725(01)00023-1 ID - Cao2001 ER - TY - JOUR AU - Folberg, R. AU - Hendrix, M. J. AU - Maniotis, A. J. PY - 2000 DA - 2000// TI - Vasculogenic mimicry and tumor angiogenesis JO - Am J Pathol VL - 156 UR - https://doi.org/10.1016/S0002-9440(10)64739-6 DO - 10.1016/S0002-9440(10)64739-6 ID - Folberg2000 ER - TY - JOUR AU - Maniotis, A. J. AU - Folberg, R. AU - Hess, A. AU - Seftor, E. A. AU - Gardner, L. M. AU - Pe’er, J. PY - 1999 DA - 1999// TI - Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry JO - Am J Pathol VL - 155 UR - https://doi.org/10.1016/S0002-9440(10)65173-5 DO - 10.1016/S0002-9440(10)65173-5 ID - Maniotis1999 ER - TY - JOUR AU - Bissell, M. J. PY - 1999 DA - 1999// TI - Tumor plasticity allows vasculogenic mimicry, a novel form of angiogenic switch. A rose by any other name? JO - Am J Pathol VL - 155 UR - https://doi.org/10.1016/S0002-9440(10)65164-4 DO - 10.1016/S0002-9440(10)65164-4 ID - Bissell1999 ER - TY - JOUR AU - Ribatti, D. AU - Vacca, A. AU - Dammacco, F. PY - 2003 DA - 2003// TI - New non-angiogenesis dependent pathways for tumour growth JO - Eur J Cancer VL - 39 UR - https://doi.org/10.1016/S0959-8049(03)00267-3 DO - 10.1016/S0959-8049(03)00267-3 ID - Ribatti2003 ER - TY - JOUR AU - Leenders, W. P. AU - Kusters, B. AU - Waal, R. M. PY - 2002 DA - 2002// TI - Vessel co-option: how tumors obtain blood supply in the absence of sprouting angiogenesis JO - Endothelium VL - 9 UR - https://doi.org/10.1080/10623320212006 DO - 10.1080/10623320212006 ID - Leenders2002 ER - TY - JOUR AU - Dome, B. AU - Paku, S. AU - Somlai, B. AU - Timar, J. PY - 2002 DA - 2002// TI - Vascularization of cutaneous melanoma involves vessel co-option and has clinical significance JO - J Pathol VL - 197 UR - https://doi.org/10.1002/path.1124 DO - 10.1002/path.1124 ID - Dome2002 ER - TY - JOUR AU - Perren, T. J. AU - Swart, A. M. AU - Pfisterer, J. AU - Ledermann, J. A. AU - Pujade-Lauraine, E. AU - Kristensen, G. PY - 2011 DA - 2011// TI - A phase 3 trial of bevacizumab in ovarian cancer JO - N Engl J Med VL - 365 UR - https://doi.org/10.1056/NEJMoa1103799 DO - 10.1056/NEJMoa1103799 ID - Perren2011 ER - TY - JOUR AU - Cataldo, V. D. AU - Gibbons, D. L. AU - Perez-Soler, R. AU - Quintas-Cardama, A. PY - 2011 DA - 2011// TI - Treatment of non-small-cell lung cancer with erlotinib or gefitinib JO - N Engl J Med VL - 364 UR - https://doi.org/10.1056/NEJMct0807960 DO - 10.1056/NEJMct0807960 ID - Cataldo2011 ER - TY - JOUR AU - Haines, I. E. AU - Miklos, G. L. PY - 2008 DA - 2008// TI - Paclitaxel plus bevacizumab for metastatic breast cancer JO - N Engl J Med VL - 358 UR - https://doi.org/10.1056/NEJMc080128 DO - 10.1056/NEJMc080128 ID - Haines2008 ER - TY - JOUR AU - Miller, K. AU - Wang, M. AU - Gralow, J. AU - Dickler, M. AU - Cobleigh, M. AU - Perez, E. A. PY - 2007 DA - 2007// TI - Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer JO - N Engl J Med VL - 357 UR - https://doi.org/10.1056/NEJMoa072113 DO - 10.1056/NEJMoa072113 ID - Miller2007 ER - TY - JOUR AU - Sandler, A. AU - Gray, R. AU - Perry, M. C. AU - Brahmer, J. AU - Schiller, J. H. AU - Dowlati, A. PY - 2006 DA - 2006// TI - Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer JO - N Engl J Med VL - 355 UR - https://doi.org/10.1056/NEJMoa061884 DO - 10.1056/NEJMoa061884 ID - Sandler2006 ER - TY - JOUR AU - Hurwitz, H. AU - Fehrenbacher, L. AU - Novotny, W. AU - Cartwright, T. AU - Hainsworth, J. AU - Heim, W. PY - 2004 DA - 2004// TI - Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer JO - N Engl J Med VL - 350 UR - https://doi.org/10.1056/NEJMoa032691 DO - 10.1056/NEJMoa032691 ID - Hurwitz2004 ER - TY - JOUR AU - Cao, Y. PY - 2014 DA - 2014// TI - VEGF-targeted cancer therapeutics-paradoxical effects in endocrine organs JO - Nat Rev Endocrinol VL - 10 UR - https://doi.org/10.1038/nrendo.2014.114 DO - 10.1038/nrendo.2014.114 ID - Cao2014 ER - TY - JOUR AU - Cao, Y. PY - 2010 DA - 2010// TI - Off-tumor target–beneficial site for antiangiogenic cancer therapy? JO - Nat Rev Clin Oncol VL - 7 UR - https://doi.org/10.1038/nrclinonc.2010.118 DO - 10.1038/nrclinonc.2010.118 ID - Cao2010 ER - TY - JOUR AU - Fidler, I. J. PY - 1991 DA - 1991// TI - Cancer metastasis JO - Br Med Bull VL - 47 ID - Fidler1991 ER - TY - JOUR AU - Lee, S. L. AU - Rouhi, P. AU - Dahl Jensen, L. AU - Zhang, D. AU - Ji, H. AU - Hauptmann, G. PY - 2009 DA - 2009// TI - Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model JO - Proc Natl Acad Sci USA VL - 106 UR - https://doi.org/10.1073/pnas.0909228106 DO - 10.1073/pnas.0909228106 ID - Lee2009 ER - TY - JOUR AU - Rouhi, P. AU - Jensen, L. D. AU - Cao, Z. AU - Hosaka, K. AU - Lanne, T. AU - Wahlberg, E. PY - 2010 DA - 2010// TI - Hypoxia-induced metastasis model in embryonic zebrafish JO - Nat Protoc VL - 5 UR - https://doi.org/10.1038/nprot.2010.150 DO - 10.1038/nprot.2010.150 ID - Rouhi2010 ER - TY - JOUR AU - Cao, Y. PY - 2005 DA - 2005// TI - Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis JO - Nat Rev Cancer VL - 5 UR - https://doi.org/10.1038/nrc1693 DO - 10.1038/nrc1693 ID - Cao2005 ER - TY - JOUR AU - Argiles, J. M. AU - Busquets, S. AU - Stemmler, B. AU - Lopez-Soriano, F. J. PY - 2014 DA - 2014// TI - Cancer cachexia: understanding the molecular basis JO - Nat Rev Cancer VL - 14 UR - https://doi.org/10.1038/nrc3829 DO - 10.1038/nrc3829 ID - Argiles2014 ER - TY - JOUR AU - Whelan, A. J. AU - Bartsch, D. AU - Goodfellow, P. J. PY - 1995 DA - 1995// TI - Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene JO - N Engl J Med VL - 333 UR - https://doi.org/10.1056/NEJM199510123331505 DO - 10.1056/NEJM199510123331505 ID - Whelan1995 ER - TY - JOUR AU - Argiles, J. M. AU - Busquets, S. AU - Lopez-Soriano, F. J. PY - 2011 DA - 2011// TI - Anti-inflammatory therapies in cancer cachexia JO - Eur J Pharmacol VL - 668 UR - https://doi.org/10.1016/j.ejphar.2011.07.007 DO - 10.1016/j.ejphar.2011.07.007 ID - Argiles2011 ER - TY - JOUR AU - Oliff, A. AU - Defeo-Jones, D. AU - Boyer, M. AU - Martinez, D. AU - Kiefer, D. AU - Vuocolo, G. PY - 1987 DA - 1987// TI - Tumors secreting human TNF/cachectin induce cachexia in mice JO - Cell VL - 50 UR - https://doi.org/10.1016/0092-8674(87)90028-6 DO - 10.1016/0092-8674(87)90028-6 ID - Oliff1987 ER - TY - JOUR AU - Zhou, X. AU - Wang, J. L. AU - Lu, J. AU - Song, Y. AU - Kwak, K. S. AU - Jiao, Q. PY - 2010 DA - 2010// TI - Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival JO - Cell VL - 142 UR - https://doi.org/10.1016/j.cell.2010.07.011 DO - 10.1016/j.cell.2010.07.011 ID - Zhou2010 ER - TY - JOUR AU - Todorov, P. AU - Cariuk, P. AU - McDevitt, T. AU - Coles, B. AU - Fearon, K. AU - Tisdale, M. PY - 1996 DA - 1996// TI - Characterization of a cancer cachectic factor JO - Nature VL - 379 UR - https://doi.org/10.1038/379739a0 DO - 10.1038/379739a0 ID - Todorov1996 ER - TY - JOUR AU - Tannock, I. F. AU - Fizazi, K. AU - Ivanov, S. AU - Karlsson, C. T. AU - Flechon, A. AU - Skoneczna, I. PY - 2013 DA - 2013// TI - Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial JO - Lancet Oncol VL - 14 UR - https://doi.org/10.1016/S1470-2045(13)70184-0 DO - 10.1016/S1470-2045(13)70184-0 ID - Tannock2013 ER - TY - JOUR AU - Garon, E. B. AU - Ciuleanu, T. E. AU - Arrieta, O. AU - Prabhash, K. AU - Syrigos, K. N. AU - Goksel, T. PY - 2014 DA - 2014// TI - Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial JO - Lancet VL - 384 UR - https://doi.org/10.1016/S0140-6736(14)60845-X DO - 10.1016/S0140-6736(14)60845-X ID - Garon2014 ER - TY - JOUR AU - Cao, Y. PY - 2009 DA - 2009// TI - Positive and negative modulation of angiogenesis by VEGFR1 ligands JO - Sci Signal VL - 2 UR - https://doi.org/10.1126/scisignal.259re1 DO - 10.1126/scisignal.259re1 ID - Cao2009 ER - TY - JOUR AU - Cao, Y. AU - Zhong, W. AU - Sun, Y. PY - 2009 DA - 2009// TI - Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance JO - Semin Cancer Biol VL - 19 UR - https://doi.org/10.1016/j.semcancer.2009.05.001 DO - 10.1016/j.semcancer.2009.05.001 ID - Cao2009 ER - TY - JOUR AU - Cao, Y. PY - 2009 DA - 2009// TI - Tumor angiogenesis and molecular targets for therapy JO - Front Biosci (Landmark Ed) VL - 14 UR - https://doi.org/10.2741/3504 DO - 10.2741/3504 ID - Cao2009 ER - TY - JOUR AU - Motzer, R. J. AU - Hutson, T. E. AU - McCann, L. AU - Deen, K. AU - Choueiri, T. K. PY - 2014 DA - 2014// TI - Overall survival in renal-cell carcinoma with pazopanib versus sunitinib JO - N Engl J Med VL - 370 UR - https://doi.org/10.1056/NEJMc1400731 DO - 10.1056/NEJMc1400731 ID - Motzer2014 ER - TY - JOUR AU - Sitohy, B. AU - Nagy, J. A. AU - Jaminet, S. C. AU - Dvorak, H. F. PY - 2011 DA - 2011// TI - Tumor-surrogate blood vessel subtypes exhibit differential susceptibility to anti-VEGF therapy JO - Cancer Res VL - 71 UR - https://doi.org/10.1158/0008-5472.CAN-11-1693 DO - 10.1158/0008-5472.CAN-11-1693 ID - Sitohy2011 ER - TY - JOUR AU - Kamba, T. AU - Tam, B. Y. AU - Hashizume, H. AU - Haskell, A. AU - Sennino, B. AU - Mancuso, M. R. PY - 2006 DA - 2006// TI - VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature JO - Am J Physiol Heart Circ Physiol VL - 290 UR - https://doi.org/10.1152/ajpheart.00133.2005 DO - 10.1152/ajpheart.00133.2005 ID - Kamba2006 ER - TY - JOUR AU - Yang, Y. AU - Zhang, Y. AU - Cao, Z. AU - Ji, H. AU - Yang, X. AU - Iwamoto, H. PY - 2013 DA - 2013// TI - Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues JO - Proc Natl Acad Sci USA VL - 110 UR - https://doi.org/10.1073/pnas.1301331110 DO - 10.1073/pnas.1301331110 ID - Yang2013 ER - TY - JOUR AU - Maynard, M. A. AU - Marino-Enriquez, A. AU - Fletcher, J. A. AU - Dorfman, D. M. AU - Raut, C. P. AU - Yassa, L. PY - 2014 DA - 2014// TI - Thyroid hormone inactivation in gastrointestinal stromal tumors JO - N Engl J Med VL - 370 UR - https://doi.org/10.1056/NEJMoa1308893 DO - 10.1056/NEJMoa1308893 ID - Maynard2014 ER - TY - JOUR AU - Jubb, A. M. AU - Pham, T. Q. AU - Hanby, A. M. AU - Frantz, G. D. AU - Peale, F. V. AU - Wu, T. D. PY - 2004 DA - 2004// TI - Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase ix in human tumours JO - J Clin Pathol VL - 57 UR - https://doi.org/10.1136/jcp.2003.012963 DO - 10.1136/jcp.2003.012963 ID - Jubb2004 ER - TY - JOUR AU - Xue, Y. AU - Religa, P. AU - Cao, R. AU - Hansen, A. J. AU - Lucchini, F. AU - Jones, B. PY - 2008 DA - 2008// TI - Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome JO - Proc Natl Acad Sci USA VL - 105 UR - https://doi.org/10.1073/pnas.0807967105 DO - 10.1073/pnas.0807967105 ID - Xue2008 ER - TY - JOUR AU - Mancuso, M. R. AU - Davis, R. AU - Norberg, S. M. AU - O’Brien, S. AU - Sennino, B. AU - Nakahara, T. PY - 2006 DA - 2006// TI - Rapid vascular regrowth in tumors after reversal of VEGF inhibition JO - J Clin Invest VL - 116 UR - https://doi.org/10.1172/JCI24612 DO - 10.1172/JCI24612 ID - Mancuso2006 ER - TY - JOUR AU - Folkman, J. PY - 1995 DA - 1995// TI - Angiogenesis in cancer, vascular, rheumatoid and other disease JO - Nat Med VL - 1 UR - https://doi.org/10.1038/nm0195-27 DO - 10.1038/nm0195-27 ID - Folkman1995 ER - TY - JOUR AU - Boehm, T. AU - Folkman, J. AU - Browder, T. AU - O’Reilly, M. S. PY - 1997 DA - 1997// TI - Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance JO - Nature VL - 390 UR - https://doi.org/10.1038/37126 DO - 10.1038/37126 ID - Boehm1997 ER - TY - JOUR AU - Ghosh, K. AU - Thodeti, C. K. AU - Dudley, A. C. AU - Mammoto, A. AU - Klagsbrun, M. AU - Ingber, D. E. PY - 2008 DA - 2008// TI - Tumor-derived endothelial cells exhibit aberrant Rho-mediated mechanosensing and abnormal angiogenesis in vitro JO - Proc Natl Acad Sci USA VL - 105 UR - https://doi.org/10.1073/pnas.0800835105 DO - 10.1073/pnas.0800835105 ID - Ghosh2008 ER - TY - JOUR AU - Casanovas, O. AU - Hicklin, D. J. AU - Bergers, G. AU - Hanahan, D. PY - 2005 DA - 2005// TI - Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors JO - Cancer Cell VL - 8 UR - https://doi.org/10.1016/j.ccr.2005.09.005 DO - 10.1016/j.ccr.2005.09.005 ID - Casanovas2005 ER - TY - JOUR AU - Crawford, Y. AU - Kasman, I. AU - Yu, L. AU - Zhong, C. AU - Wu, X. AU - Modrusan, Z. PY - 2009 DA - 2009// TI - PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment JO - Cancer Cell VL - 15 UR - https://doi.org/10.1016/j.ccr.2008.12.004 DO - 10.1016/j.ccr.2008.12.004 ID - Crawford2009 ER - TY - JOUR AU - Blouw, B. AU - Song, H. AU - Tihan, T. AU - Bosze, J. AU - Ferrara, N. AU - Gerber, H. P. PY - 2003 DA - 2003// TI - The hypoxic response of tumors is dependent on their microenvironment JO - Cancer Cell VL - 4 UR - https://doi.org/10.1016/S1535-6108(03)00194-6 DO - 10.1016/S1535-6108(03)00194-6 ID - Blouw2003 ER - TY - JOUR AU - Stacker, S. A. AU - Achen, M. G. PY - 2013 DA - 2013// TI - The vegf signaling pathway in cancer: the road ahead JO - Chin J Cancer VL - 32 ID - Stacker2013 ER - TY - JOUR AU - Chen, Y. S. AU - Chen, Z. P. PY - 2014 DA - 2014// TI - Vasculogenic mimicry: a novel target for glioma therapy JO - Chin J Cancer VL - 33 UR - https://doi.org/10.5732/cjc.012.10292 DO - 10.5732/cjc.012.10292 ID - Chen2014 ER - TY - JOUR AU - Donnem, T. AU - Hu, J. AU - Ferguson, M. AU - Adighibe, O. AU - Snell, C. AU - Harris, A. L. PY - 2013 DA - 2013// TI - Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment? JO - Cancer Med VL - 2 UR - https://doi.org/10.1002/cam4.105 DO - 10.1002/cam4.105 ID - Donnem2013 ER - TY - JOUR AU - Nissen, L. J. AU - Cao, R. AU - Hedlund, E. M. AU - Wang, Z. AU - Zhao, X. AU - Wetterskog, D. PY - 2007 DA - 2007// TI - Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis JO - J Clin Invest VL - 117 UR - https://doi.org/10.1172/JCI32479 DO - 10.1172/JCI32479 ID - Nissen2007 ER - TY - JOUR AU - Cao, R. AU - Brakenhielm, E. AU - Pawliuk, R. AU - Wariaro, D. AU - Post, M. J. AU - Wahlberg, E. PY - 2003 DA - 2003// TI - Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2 JO - Nat Med VL - 9 UR - https://doi.org/10.1038/nm848 DO - 10.1038/nm848 ID - Cao2003 ER - TY - JOUR AU - Kerbel, R. S. PY - 2006 DA - 2006// TI - Antiangiogenic therapy: a universal chemosensitization strategy for cancer? JO - Science VL - 312 UR - https://doi.org/10.1126/science.1125950 DO - 10.1126/science.1125950 ID - Kerbel2006 ER - TY - JOUR AU - Jain, R. K. PY - 2005 DA - 2005// TI - Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy JO - Science VL - 307 UR - https://doi.org/10.1126/science.1104819 DO - 10.1126/science.1104819 ID - Jain2005 ER - TY - JOUR AU - Winkler, F. AU - Kozin, S. V. AU - Tong, R. T. AU - Chae, S. S. AU - Booth, M. F. AU - Garkavtsev, I. PY - 2004 DA - 2004// TI - Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases JO - Cancer Cell VL - 6 ID - Winkler2004 ER - TY - JOUR AU - Ebos, J. M. AU - Lee, C. R. AU - Cruz-Munoz, W. AU - Bjarnason, G. A. AU - Christensen, J. G. AU - Kerbel, R. S. PY - 2009 DA - 2009// TI - Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis JO - Cancer Cell VL - 15 UR - https://doi.org/10.1016/j.ccr.2009.01.021 DO - 10.1016/j.ccr.2009.01.021 ID - Ebos2009 ER - TY - JOUR AU - Paez-Ribes, M. AU - Allen, E. AU - Hudock, J. AU - Takeda, T. AU - Okuyama, H. AU - Vinals, F. PY - 2009 DA - 2009// TI - Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis JO - Cancer Cell VL - 15 UR - https://doi.org/10.1016/j.ccr.2009.01.027 DO - 10.1016/j.ccr.2009.01.027 ID - Paez-Ribes2009 ER - TY - JOUR AU - Zhang, D. AU - Hedlund, E. M. AU - Lim, S. AU - Chen, F. AU - Zhang, Y. AU - Sun, B. PY - 2011 DA - 2011// TI - Antiangiogenic agents significantly improve survival in tumor-bearing mice by increasing tolerance to chemotherapy-induced toxicity JO - Proc Natl Acad Sci USA VL - 108 UR - https://doi.org/10.1073/pnas.1016220108 DO - 10.1073/pnas.1016220108 ID - Zhang2011 ER - TY - JOUR AU - Ribatti, D. PY - 2010 DA - 2010// TI - Erythropoietin and tumor angiogenesis JO - Stem Cells Dev VL - 19 UR - https://doi.org/10.1089/scd.2009.0402 DO - 10.1089/scd.2009.0402 ID - Ribatti2010 ER - TY - JOUR AU - Garcia-Donas, J. AU - Rodriguez-Antona, C. AU - Jonasch, E. PY - 2013 DA - 2013// TI - Molecular markers to predict response to therapy JO - Semin Oncol VL - 40 UR - https://doi.org/10.1053/j.seminoncol.2013.05.005 DO - 10.1053/j.seminoncol.2013.05.005 ID - Garcia-Donas2013 ER - TY - JOUR AU - Maru, D. AU - Venook, A. P. AU - Ellis, L. M. PY - 2013 DA - 2013// TI - Predictive biomarkers for bevacizumab: are we there yet? JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-12-3409 DO - 10.1158/1078-0432.CCR-12-3409 ID - Maru2013 ER - TY - JOUR AU - Pohl, M. AU - Werner, N. AU - Munding, J. AU - Tannapfel, A. AU - Graeven, U. AU - Nickenig, G. PY - 2011 DA - 2011// TI - Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature JO - Z Gastroenterol VL - 49 UR - https://doi.org/10.1055/s-0031-1281752 DO - 10.1055/s-0031-1281752 ID - Pohl2011 ER - TY - JOUR AU - Niers, T. M. AU - Richel, D. J. AU - Meijers, J. C. AU - Schlingemann, R. O. PY - 2011 DA - 2011// TI - Vascular endothelial growth factor in the circulation in cancer patients may not be a relevant biomarker JO - PLoS ONE VL - 6 UR - https://doi.org/10.1371/journal.pone.0019873 DO - 10.1371/journal.pone.0019873 ID - Niers2011 ER - TY - JOUR AU - Denduluri, N. AU - Yang, S. X. AU - Berman, A. W. AU - Nguyen, D. AU - Liewehr, D. J. AU - Steinberg, S. M. PY - 2008 DA - 2008// TI - Circulating biomarkers of bevacizumab activity in patients with breast cancer JO - Cancer Biol Ther VL - 7 UR - https://doi.org/10.4161/cbt.7.1.5337 DO - 10.4161/cbt.7.1.5337 ID - Denduluri2008 ER - TY - JOUR AU - Hegde, P. S. AU - Jubb, A. M. AU - Chen, D. AU - Li, N. F. AU - Meng, Y. G. AU - Bernaards, C. PY - 2013 DA - 2013// TI - Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-12-2535 DO - 10.1158/1078-0432.CCR-12-2535 ID - Hegde2013 ER - TY - JOUR AU - Bunni, J. AU - Shelley-Fraser, G. AU - Stevenson, K. AU - Oltean, S. AU - Salmon, A. AU - Harper, S. J. PY - 2015 DA - 2015// TI - Circulating levels of anti-angiogenic VEGF-A isoform (VEGF-AXXXB) in colorectal cancer patients predicts tumour VEGF-A ratios JO - Am J Cancer Res VL - 5 ID - Bunni2015 ER - TY - JOUR AU - Lambrechts, D. AU - Lenz, H. J. AU - Haas, S. AU - Carmeliet, P. AU - Scherer, S. J. PY - 2013 DA - 2013// TI - Markers of response for the antiangiogenic agent bevacizumab JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.46.2762 DO - 10.1200/JCO.2012.46.2762 ID - Lambrechts2013 ER - TY - JOUR AU - Chen, C. AU - Sun, P. AU - Ye, S. AU - Weng, H. W. AU - Dai, Q. S. PY - 2014 DA - 2014// TI - Hypertension as a predictive biomarker for efficacy of bevacizumab treatment in metastatic colorectal cancer: a meta-analysis JO - J BUON VL - 19 ID - Chen2014 ER - TY - JOUR AU - Penzvalto, Z. AU - Surowiak, P. AU - Gyorffy, B. PY - 2014 DA - 2014// TI - Biomarkers for systemic therapy in ovarian cancer JO - Curr Cancer Drug Targets VL - 14 UR - https://doi.org/10.2174/1568009614666140310120107 DO - 10.2174/1568009614666140310120107 ID - Penzvalto2014 ER - TY - JOUR AU - Gampenrieder, S. P. AU - Romeder, F. AU - Muss, C. AU - Pircher, M. AU - Ressler, S. AU - Rinnerthaler, G. PY - 2014 DA - 2014// TI - Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis JO - Anticancer Res VL - 34 ID - Gampenrieder2014 ER - TY - JOUR AU - Tahover, E. AU - Uziely, B. AU - Salah, A. AU - Temper, M. AU - Peretz, T. AU - Hubert, A. PY - 2013 DA - 2013// TI - Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients JO - Med Oncol VL - 30 UR - https://doi.org/10.1007/s12032-012-0327-4 DO - 10.1007/s12032-012-0327-4 ID - Tahover2013 ER - TY - JOUR AU - Lombardi, G. AU - Zustovich, F. AU - Farina, P. AU - Fiduccia, P. AU - Della Puppa, A. AU - Polo, V. PY - 2013 DA - 2013// TI - Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature JO - Anticancer Drugs VL - 24 UR - https://doi.org/10.1097/CAD.0b013e32835aa5fd DO - 10.1097/CAD.0b013e32835aa5fd ID - Lombardi2013 ER - TY - JOUR AU - Mir, O. AU - Coriat, R. AU - Cabanes, L. AU - Ropert, S. AU - Billemont, B. AU - Alexandre, J. PY - 2011 DA - 2011// TI - An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity JO - Oncologist VL - 16 UR - https://doi.org/10.1634/theoncologist.2010-0002 DO - 10.1634/theoncologist.2010-0002 ID - Mir2011 ER - TY - JOUR AU - Osterlund, P. AU - Soveri, L. M. AU - Isoniemi, H. AU - Poussa, T. AU - Alanko, T. AU - Bono, P. PY - 2011 DA - 2011// TI - Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy JO - Br J Cancer VL - 104 UR - https://doi.org/10.1038/bjc.2011.2 DO - 10.1038/bjc.2011.2 ID - Osterlund2011 ER - TY - JOUR AU - Tol, J. AU - Koopman, M. AU - Cats, A. AU - Rodenburg, C. J. AU - Creemers, G. J. AU - Schrama, J. G. PY - 2009 DA - 2009// TI - Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer JO - N Engl J Med VL - 360 UR - https://doi.org/10.1056/NEJMoa0808268 DO - 10.1056/NEJMoa0808268 ID - Tol2009 ER -